{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:53Z","timestamp":1790198513847,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41375-018-0175-0","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T09:22:44Z","timestamp":1529486564000},"page":"1643-1656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML"],"prefix":"10.1038","volume":"32","author":[{"given":"Oscar","family":"Br\u00fcck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Dufva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Turkki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Chheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panu","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-9769","authenticated-orcid":false,"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-0332","authenticated-orcid":false,"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teijo","family":"Pellinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"175_CR1","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saussele","year":"2016","unstructured":"Saussele S, Richter J, Hochhaus A, Mahon F-X. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638\u201347.","journal-title":"Leukemia"},{"key":"175_CR2","first-page":"1","volume":"2045","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;2045:1\u201311.","journal-title":"Lancet Oncol"},{"key":"175_CR3","first-page":"1","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8:1\u201312.","journal-title":"Front Immunol"},{"key":"175_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI200316398","volume":"111","author":"JJ Molldrem","year":"2003","unstructured":"Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111:639\u201347.","journal-title":"J Clin Invest"},{"key":"175_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018\u201323.","journal-title":"Nat Med"},{"key":"175_CR6","first-page":"17","volume":"1","author":"A Kreutzman","year":"2013","unstructured":"Kreutzman A, Porkka K, Mustjoki S. Immunomodulatory effects of tyrosine kinase inhibitors. Int Trends Immun. 2013;1:17\u201328.","journal-title":"Int Trends Immun"},{"key":"175_CR7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017;129:1166\u201376.","journal-title":"Blood"},{"key":"175_CR8","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1038\/leu.2017.235","volume":"31","author":"S Sopper","year":"2017","unstructured":"Sopper S, Mustjoki S, Gjertsen BT, Giles F, Hochhaus A, Janssen JJWM, et al. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2017;31:2264\u20137.","journal-title":"Leukemia"},{"key":"175_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","volume":"35","author":"S Sopper","year":"2016","unstructured":"Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, et al. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2016;35:175\u201384.","journal-title":"J Clin Oncol"},{"key":"175_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H, Guilhot J, Br\u00fcck O, L\u00e4hteenm\u00e4ki H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108\u201316.","journal-title":"Leukemia"},{"key":"175_CR11","first-page":"1","volume":"32","author":"C Sch\u00fctz","year":"2017","unstructured":"Sch\u00fctz C, Inselmann S, Sausslele S, Dietz CT, M\u00fcller MC, Eigendorff E, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;32:1\u20138.","journal-title":"Leukemia"},{"key":"175_CR12","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528\u2013e535.","journal-title":"Lancet Haematol"},{"key":"175_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/ejh.12258","volume":"92","author":"P Koskenvesa","year":"2014","unstructured":"Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, R\u00e4s\u00e4nen A, et al. Imatinib and pegylated IFN-\u03b12b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. 2014;92:413\u201320.","journal-title":"Eur J Haematol"},{"key":"175_CR14","doi-asserted-by":"crossref","unstructured":"Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. 2017.","DOI":"10.3324\/haematol.2017.165001"},{"key":"175_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","volume":"43","author":"G Caocci","year":"2015","unstructured":"Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, et al. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol. 2015;43:1015\u20138.","journal-title":"Exp Hematol"},{"key":"175_CR16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/cas.12216","volume":"104","author":"I Mizoguchi","year":"2013","unstructured":"Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013;104:1146\u201353.","journal-title":"Cancer Sci"},{"key":"175_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, et al. Prognosis for patients with CML and 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511\u20138.","journal-title":"Blood"},{"key":"175_CR18","first-page":"1809","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Leukemia. 2006;108:1809\u201320.","journal-title":"Leukemia"},{"key":"175_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999\u20131003.","journal-title":"Leukemia"},{"key":"175_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15798-4","volume":"7","author":"S Blom","year":"2017","unstructured":"Blom S, Paavolainen L, Bychkov D, Turkki R, M\u00e4ki-Teeri P, Hemmes A, et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci Rep. 2017;7:15580.","journal-title":"Sci Rep"},{"key":"175_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"AE Carpenter","year":"2006","unstructured":"Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100.","journal-title":"Genome Biol"},{"key":"175_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1109\/RBME.2016.2515127","volume":"9","author":"F Xing","year":"2016","unstructured":"Xing F, Member S, Yang L. Robust nucleus\/cell detection and segmentation in digital pathology and microscopy images: a comprehensive review. IEEE Rev Biomed Eng. 2016;9:234\u201363.","journal-title":"IEEE Rev Biomed Eng"},{"key":"175_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nmeth.4397","volume":"14","author":"JC Caicedo","year":"2017","unstructured":"Caicedo JC, Cooper S, Heigwer F, Warchal S, Qiu P, Molnar C, et al. Data-analysis strategies for image-based cell profiling. Nat Methods. 2017;14:849\u201363.","journal-title":"Nat Methods"},{"key":"175_CR24","first-page":"289","volume":"57","author":"YB Yosef","year":"2017","unstructured":"Yosef YB, H. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 2017;57:289\u2013300.","journal-title":"J R Stat Soc Ser B"},{"key":"175_CR25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression selection and shrinkage via the lasso. J R Stat Soc B. 1996;58:267\u201388.","journal-title":"J R Stat Soc B"},{"key":"175_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S1470-2045(16)30560-5","volume":"18","author":"J Guinney","year":"2017","unstructured":"Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2017;18:132\u201342.","journal-title":"Lancet Oncol"},{"key":"175_CR27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cjs.10046","volume":"38","author":"H Hung","year":"2009","unstructured":"Hung H, Chin\u2010Tsang C. Estimation methods for time\u2010dependent AUC models with survival data. Can J Stat. 2009;38:8\u201326.","journal-title":"Can J Stat"},{"key":"175_CR28","volume-title":"RStudio: Integrated Development for R","author":"RStudio Team.","year":"2015","unstructured":"RStudio Team. RStudio: Integrated Development for R. Boston, MA: RStudio, Inc.; 2015."},{"key":"175_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2015","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2015;30:48\u201356.","journal-title":"Leukemia"},{"key":"175_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:1\u201310.","journal-title":"Nat Commun"},{"key":"175_CR31","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"175_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"175_CR33","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"175_CR34","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/leu.2013.19","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 2013;27:1520\u20136.","journal-title":"Leukemia"},{"key":"175_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0022-1759(03)00202-3","volume":"278","author":"A Costantini","year":"2003","unstructured":"Costantini A, Mancini S, Giuliodoro S, Butini L, Regnery CM, Silvestri G, et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods. 2003;278:145\u201355.","journal-title":"J Immunol Methods"},{"key":"175_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, S\u00f6derlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS ONE. 2013;8:1\u201312.","journal-title":"PLoS ONE"},{"key":"175_CR37","first-page":"1","volume":"2016","author":"JX Song","year":"2016","unstructured":"Song J-X, Dian Z-J, Wen Y, Mei F, Li R-W, Sa Y-L. Assessment of the number and phenotype of macrophages in the human BMB samples of CML. Biomed Res Int. 2016;2016:1\u20139.","journal-title":"Biomed Res Int"},{"key":"175_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860.","journal-title":"Nature"},{"key":"175_CR39","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014\u201322.","journal-title":"Nat Immunol"},{"key":"175_CR40","doi-asserted-by":"publisher","first-page":"1528 LP","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Sch\u00fcrch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia\u2013specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114:1528 LP\u20131536.","journal-title":"Blood"},{"key":"175_CR41","doi-asserted-by":"publisher","first-page":"e1065368","DOI":"10.1080\/2162402X.2015.1065368","volume":"5","author":"SAE Held","year":"2016","unstructured":"Held SAE, Heine A, Kesper AR, Sch\u00f6nberg K, Beckers A, Wolf D, et al. Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors. Oncoimmunology. 2016;5:e1065368.","journal-title":"Oncoimmunology"},{"key":"175_CR42","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.20121229","volume":"210","author":"C Sch\u00fcrch","year":"2013","unstructured":"Sch\u00fcrch C, Riether C, Amrein MA, Ochsenbein AF. Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-\u03b3. J Exp Med. 2013;210:605\u201321.","journal-title":"J Exp Med"},{"key":"175_CR43","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/leu.2015.26","volume":"29","author":"C Riether","year":"2015","unstructured":"Riether C, Gschwend T, Huguenin A-L, Sch\u00fcrch CM, Ochsenbein AF. Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. Leukemia. 2015;29:1781\u20135.","journal-title":"Leukemia"},{"key":"175_CR44","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","volume":"181","author":"N Larmonier","year":"2008","unstructured":"Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol. 2008;181:6955\u201363.","journal-title":"J Immunol"},{"key":"175_CR45","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/nm.2438","volume":"17","author":"VP Balachandran","year":"2011","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094\u20131100.","journal-title":"Nat Med"},{"key":"175_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","volume":"5","author":"C Hekim","year":"2017","unstructured":"Hekim C, Ilander M, Yan J, Michaud E, Smykla R, V\u00e4h\u00e4-Koskela M, et al. Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models. Cancer Immunol Res. 2017;5:157\u201369.","journal-title":"Cancer Immunol Res"},{"key":"175_CR47","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27:914\u201324.","journal-title":"Leukemia"},{"key":"175_CR48","doi-asserted-by":"publisher","first-page":"e28925","DOI":"10.4161\/onci.28925","volume":"3","author":"A Kreutzman","year":"2014","unstructured":"Kreutzman A, Ilander M, Porkka K, Vakkila J, Mustjoki S. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology. 2014;3:e28925.","journal-title":"Oncoimmunology"},{"key":"175_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298\u2013306.","journal-title":"Nat Rev Cancer"},{"key":"175_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-205","volume":"10","author":"J Galon","year":"2012","unstructured":"Galon J, Pag\u00e8s F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205.","journal-title":"J Transl Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0175-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T16:06:57Z","timestamp":1720368417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0175-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0175-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"3 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.P. has received honoraria and research funding from Pfizer, Novartis and Bristol-Myers Squibb. S.M. has received honoraria and research funding from Pfizer, Novartis, and Bristol-Myers Squibb. S.B. has received consultant fees from Fimmic. T.A. has received research funding from Novartis. P.Kos. has received honoraria from Novartis, Pfizer, and Incyte.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}